NASDAQ:AMGNAmgen Stock Price, Forecast & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 18.1% and is now trading at $234.65.
View which stocks have been most impacted by COVID-19.

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, July, 28th. The medical research company reported $4.25 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.81 by $0.44. The medical research company earned $6.21 billion during the quarter, compared to analyst estimates of $6.19 billion. Amgen had a return on equity of 91.98% and a net margin of 30.04%. Amgen's revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.97 EPS.
View Amgen's earnings history.

Amgen declared a quarterly dividend on Thursday, July 23rd. Investors of record on Monday, August 17th will be paid a dividend of $1.60 per share on Tuesday, September 8th. This represents a $6.40 annualized dividend and a dividend yield of 2.73%. The ex-dividend date of this dividend is Friday, August 14th.
View Amgen's dividend history.

Amgen issued an update on its FY20 earnings guidance on Tuesday, July, 28th. The company provided EPS guidance of $15.10-15.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.63. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.38 billion.

29 Wall Street analysts have issued 12-month price objectives for Amgen's shares. Their forecasts range from $185.00 to $300.00. On average, they anticipate Amgen's share price to reach $253.65 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price.
View analysts' price targets for Amgen.

News stories about AMGN stock have trended extremely negative this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amgen earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about Amgen.

Amgen saw a drop in short interest in May. As of May 15th, there was short interest totaling 7,010,000 shares, a drop of 11.0% from the April 30th total of 7,880,000 shares. Based on an average daily trading volume, of 3,490,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.2% of the company's stock are short sold.
View Amgen's Short Interest.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.14%), LSV Asset Management (0.49%), Sumitomo Mitsui Trust Holdings Inc. (0.46%), Swiss National Bank (0.40%), PNC Financial Services Group Inc. (0.29%) and California Public Employees Retirement System (0.23%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar and Tyler Jacks.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Toronto Dominion Bank, LSV Asset Management, Healthcare of Ontario Pension Plan Trust Fund, Natixis Advisors L.P., State of Wisconsin Investment Board, MERIAN GLOBAL INVESTORS UK Ltd, and Envestnet Asset Management Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., Robeco Institutional Asset Management B.V., Thrivent Financial for Lutherans, Sumitomo Mitsui Trust Holdings Inc., Bank of New York Mellon Corp, Wedge Capital Management L L P NC, Cullinan Associates Inc., and Principal Financial Group Inc..
View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $234.65.

Amgen has a market capitalization of $137.43 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]